GO
Loading...

Biotechnology

More

  • Alibaba symbol of China's new tech giants Thursday, 18 Sep 2014 | 4:17 AM ET

    BEIJING— Alibaba Group's U.S. stock offering is a wakeup call about an emerging wave of technology giants in China's state-dominated economy. By contrast, private sector tech champions such as Lenovo Group in personal computers and search engine Baidu Inc. survived bruising competition to rise to the top of their industries.

  • 3 Biotech picks: Gilead, Biogen & Celgene     Friday, 5 Sep 2014 | 12:54 PM ET

    Breaking down the hottest stocks in biotech now, with John Schroer, Allianz Global Investors.

  • Race for cholesterol drugs     Tuesday, 2 Sep 2014 | 8:17 AM ET

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • Why US biotech stocks are back in favor     Monday, 25 Aug 2014 | 7:16 PM ET

    While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.

  • Roche's blockbuster pharma deal     Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • What Roche gets from InterMune     Monday, 25 Aug 2014 | 10:09 AM ET

    Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.

  • Roche's $8.3 billion deal for InterMune     Monday, 25 Aug 2014 | 9:06 AM ET

    Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.

  • Big change for pain drugs     Friday, 22 Aug 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.

  • Hot biotech drugs     Tuesday, 19 Aug 2014 | 7:07 AM ET

    CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.

  • Fighting obesity with Rxs     Monday, 18 Aug 2014 | 2:17 PM ET

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Red hot biotech stocks     Thursday, 14 Aug 2014 | 3:10 PM ET

    CNBC's Morgan Brennan runs through today's big biotech movers.

  • Time to buy biotech?     Wednesday, 13 Aug 2014 | 4:38 PM ET

    Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.

  • Biotechs race for Ebola cure     Monday, 11 Aug 2014 | 5:30 PM ET

    CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.

  • Merck & Pfizer beat the Street     Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • What's coming in biotech?     Wednesday, 23 Jul 2014 | 2:15 PM ET

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.

  • CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges     Wednesday, 23 Jul 2014 | 10:39 AM ET

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Analyst calls out Yellen's biotech comments     Friday, 18 Jul 2014 | 12:45 PM ET

    Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.

  • How will Yellen's comments impact US stocks?     Tuesday, 15 Jul 2014 | 11:34 PM ET

    Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.